

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Aeris Technologies Ltd</b>
<b>ABN</b>	<b>19 093 977 336</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Maurie Stang
<b>Date of last notice</b>	5 September 2002

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect interests
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect interest in securities held by Novapharm Research (Australia) Pty Ltd. Maurie Stang is a director and part owner of Novapharm Research (Australia) Pty Ltd. Indirect interest through Epitek Pty Ltd. Maurie Stang has a material interest in Epitek Pty Ltd. Securities held by Gryphon Capital as trustee of The G-A Trust. Maurie Stang is owner and sole director of Gryphon Capital.
<b>Date of change</b>	12 July 2005
<b>No. of securities held prior to change</b>	9,283,000 ordinary shares 8,147,767 options
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	8,147,767 shares after exercising 8,147,767 options
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$0.20 per share
<b>No. of securities held after change</b>	17,430,767 ordinary shares, 0 options

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice - M Stang**

---

<p><b>Nature of change</b>          Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p><b>Exercise of options</b></p>
--	-----------------------------------

**Part 2 – Change of director's interests in contracts**

<b>Detail of contract</b>	Nil
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

M Stang – 19 July 2005

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Aeris Technologies Ltd</b>
<b>ABN</b>	19 093 977 336

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Steven Kritzler
<b>Date of last notice</b>	1 October 2002

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect interest in securities held by the S Kritzler Family Trust and held by Novapharm Research (Australia) Pty Ltd. S Kritzler is a beneficiary of the S Kritzler Family Trust and a director and part owner of Novapharm Research (Australia) Pty Ltd.
<b>Date of change</b>	12 July 2005
<b>No. of securities held prior to change</b>	7,106,000 ordinary shares 6,371,609 options
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	6,371,609 shares after exercising 6,371,609 options
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$0.20 per share
<b>No. of securities held after change</b>	13,477,609 ordinary shares 0 options

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice – S Kritzler**

---

<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<b>Exercise of options</b>
---	----------------------------

**Part 2 – Change of director's interests in contracts**

<b>Detail of contract</b>	Nil
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

S Kritzler – 19 July 2005

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Aeris Technologies Ltd</b>
<b>ABN</b>	19 093 977 336

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Bernard Stang
<b>Date of last notice</b>	1 October 2002

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect interest in securities held by Novapharm Research (Australia) Pty Ltd. Bernard Stang is a director and part owner of this company. Indirect interest through Epitek Pty Ltd. Bernard Stang has a material interest in Epitek Pty Ltd.
<b>Date of change</b>	12 July 2005
<b>No. of securities held prior to change</b>	7,171,000 ordinary shares 6,371,609 options
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	6,371,609 shares after exercising 6,371,609 options
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$0.20 per share
<b>No. of securities held after change</b>	13,542,609 ordinary shares, 0 options

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<p><b>Nature of change</b>          Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p><b>Exercise of options</b></p>
--	-----------------------------------

**Part 2 – Change of director's interests in contracts**

<p><b>Detail of contract</b></p>	<p>Nil</p>
<p><b>Nature of interest</b></p>	
<p><b>Name of registered holder (if issued securities)</b></p>	
<p><b>Date of change</b></p>	
<p><b>No. and class of securities to which interest related prior to change</b>          Note: Details are only required for a contract in relation to which the interest has changed</p>	
<p><b>Interest acquired</b></p>	
<p><b>Interest disposed</b></p>	
<p><b>Value/Consideration</b>          Note: If consideration is non-cash, provide details and an estimated valuation</p>	
<p><b>Interest after change</b></p>	

B Stang – 19 July 2005

---

+ See chapter 19 for defined terms.